Arrowhead Pharmaceuticals (ARWR) said Monday it dosed the first patients in a phase 1/2a clinical trial of ARO-INHBE, the company's investigational therapy to counter obesity.
The study will treat patients with ARO-INHBE as monotherapy in part 1 and in combination with tirzepatide in part 2.
The company also recently filed for regulatory clearance to launch a clinical trial of its second obesity candidate, ARO-ALK7.
Shares of the company were up more than 2.5% in Monday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.